Frontiers in dental medicine · 2026
Glucosamine supplementation in the treatment of temporomandibular joint disorders: a systematic review and meta-analysis.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Calzada-Gonzales Nancy, Aguirre-Ipenza Rubén, Serna-Alarcón Victor, Valeriano-Mamani Jordan, Mendoza-Torres Rocio, Hueda-Zavaleta Miguel, Taype-Rondan Alvaro, Brañez-Condorena Ana, Alarcon-Ruiz Christoper A
Аннотация
BACKGROUND: Glucosamine has been proposed as a therapeutic option for temporomandibular disorders (TMD), particularly temporomandibular joint osteoarthritis (TMJ OA), but its effectiveness and safety remain uncertain.
OBJECTIVE: To evaluate the benefits and harms of oral glucosamine supplementation in patients with TMJ OA and other/unspecified TMD.
METHODS: A systematic review was conducted in PubMed/MEDLINE, CENTRAL, Scopus, and Embase through October 8, 2025. Randomized controlled trials (RCTs) evaluating oral glucosamine supplementation in patients with any type of TMD, including TMJ OA, were selected. Meta-analyses were performed using random-effects models, and the GRADE methodology was applied to assess the certainty of the evidence.
RESULTS: Seven RCTs were included. In patients with TMJ OA, compared with placebo, glucosamine may not result in a clinically important reduction in pain at ≤3 months (MD -1.58 mm; 95% CI -5.98 to 2.83; low certainty) and probably does not provide a clinically important reduction at 6 months despite statistical significance (MD -7.02 mm; 95% CI -11.95 to -2.09; moderate certainty). Glucosamine improved quality of life at 12 months (MD -4.14; 95% CI -6.41 to -1.87; high certainty). Compared with active controls, the effect on pain was uncertain, although quality of life may improve at 3 months. In patients with other/unspecified TMD, glucosamine may not meaningfully reduce pain but may increase maximum pain-free mandibular opening at 3 months. Evidence regarding adverse and serious adverse events was very uncertain across comparisons.
CONCLUSION: Oral glucosamine does not provide a clinically important reduction in pain in TMJ OA or other/unspecified TMD but may improve quality of life in TMJ OA. Evidence for functional outcomes and adverse events remains uncertain, highlighting the need for high-quality randomized trials.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024531131, identifier CRD42024531131.
OBJECTIVE: To evaluate the benefits and harms of oral glucosamine supplementation in patients with TMJ OA and other/unspecified TMD.
METHODS: A systematic review was conducted in PubMed/MEDLINE, CENTRAL, Scopus, and Embase through October 8, 2025. Randomized controlled trials (RCTs) evaluating oral glucosamine supplementation in patients with any type of TMD, including TMJ OA, were selected. Meta-analyses were performed using random-effects models, and the GRADE methodology was applied to assess the certainty of the evidence.
RESULTS: Seven RCTs were included. In patients with TMJ OA, compared with placebo, glucosamine may not result in a clinically important reduction in pain at ≤3 months (MD -1.58 mm; 95% CI -5.98 to 2.83; low certainty) and probably does not provide a clinically important reduction at 6 months despite statistical significance (MD -7.02 mm; 95% CI -11.95 to -2.09; moderate certainty). Glucosamine improved quality of life at 12 months (MD -4.14; 95% CI -6.41 to -1.87; high certainty). Compared with active controls, the effect on pain was uncertain, although quality of life may improve at 3 months. In patients with other/unspecified TMD, glucosamine may not meaningfully reduce pain but may increase maximum pain-free mandibular opening at 3 months. Evidence regarding adverse and serious adverse events was very uncertain across comparisons.
CONCLUSION: Oral glucosamine does not provide a clinically important reduction in pain in TMJ OA or other/unspecified TMD but may improve quality of life in TMJ OA. Evidence for functional outcomes and adverse events remains uncertain, highlighting the need for high-quality randomized trials.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024531131, identifier CRD42024531131.